Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 987
countries
28
conditions
2 109

988 trials match your criteria

Pancreatic carcinoma metastatic

Recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Non-small cell lung cancer stage I

Recruiting

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157

Amyotrophic lateral sclerosis

Recruiting

A study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin

Chronic spontaneous urticaria

Recruiting

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

Amyotrophic lateral sclerosis

Recruiting

A study to evaluate the effectiveness and safety of usnoflast in adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Usnoflast

Colorectal cancer metastatic

Recruiting

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bevacizumab

Non-small cell lung cancer+1

Recruiting

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Recruiting

A study of navenibart for long-term safety in patients with hereditary angioedema

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Navenibart

Pancreatic neuroendocrine tumour

Recruiting

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Uveal melanoma

Recruiting

A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.